Lanean...
Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases
Ovarian cancer is the second the most common gynaecological malignancy in developed countries. 70% of patients relapse in the first 3 years following debulking surgery and first-line chemotherapy. Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthet...
Gorde:
| Argitaratua izan da: | BMJ Case Rep |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMJ Publishing Group
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6721186/ https://ncbi.nlm.nih.gov/pubmed/31466953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-230738 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|